GlassScriptPhysician profile
Mahmud M Ibrahim
NPI 1669633558
$4,943.25
in general payments reported to CMS, 2019-2025
21 companies · $299 in 2025
The $299 reported for 2025 was more than what 77% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
See the full distribution for Sports Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $181 · 2021: $413 · 2022: $540 · 2023: $437 · 2024: $2,567 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Travel and Lodging: $1,185 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.22 |
| Travel and Lodging | $1,184.88 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,439.39 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $1,013.82 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $846.49 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Protega Pharmaceutials INC | $779.09 | 2023-2025 | Roxybond |
| Medtronic, INC. | $230.71 | 2024 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $136.13 | 2020-2021 | |
| Forte Bio-Pharma LLC | $115.18 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.59 | 2022-2023 | Relistor |
| Nevro Corp. | $54.67 | 2023-2024 | Senza |
| Depuy Synthes Sales INC. | $51.77 | 2023-2025 | Monovisc, Orthovisc |
| Bioventus LLC | $41.76 | 2024-2025 | Gelsyn-3, Durolane |
| Avanos Medical | $39.75 | 2022-2024 | Trays- All |
| Pfizer INC. | $29.09 | 2019 | |
| Medtronic USA, INC. | $18.71 | 2019 | |
| Virtus Pharmaceuticals LLC | $16.26 | 2025 | Levorphanol Tartrate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.31 | 2023 | |
| Kaleo, INC. | $14.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.57 | 2020 | |
| Abbott Laboratories | $13.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2020 | |
| Electronic Waveform Lab, INC. | $7.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmud Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.